Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunomedics has announced that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy or ER-CHOP, for the therapy of patients with newly diagnosed diffuse large B-cell lymphoma produced promising results.
Subscribe to our email newsletter
Seventy-eight patients with previously untreated diffuse large B-cell lymphoma were eligible to participate in this Phase II open-label study led by Mayo Clinic, Rochester, Minnesota.
The primary endpoint of this study is event-free survival (EFS) at 12 months with planned interim analysis after 34 evaluable patients. At the time of reporting, EFS for 34 interim analysis patients was 85% (29 out of 34). Overall, 95% of patients responded (72 out of 76), including 47 complete responses (62%) and 25 partial responses (33%).
Interim results show that the overall response rate and EFS at 12 months for ER-CHOP, in comparison to R-CHOP, are promising. Patients received epratuzumab at 360 mg/m2, followed by rituximab at 375 mg/m2, and a standard dose of CHOP every 3 weeks for 6 cycles.
The ER-CHOP regimen, which was easily administered to patients, was found to be safe with little added toxicity over R-CHOP. Overall response rate was 87% (13 out of 15) with event-free survival and overall survival at one year of 93% and 100%, respectively.